Series Editor:
Clive Page, King's College London, U.K.
Edited by
Christian Schudt, Byk Gulden Pharmaceuticals, Konstan, Germany
Gordon Dent, Kraankenhaus Grobhansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, Germany
Klaus Rabe, Kraankenhaus Grobhansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, Germany
Description
Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In
the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors.
Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular
biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well
as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable
PDE inhibitor for their research or who is dealing with such drugs in a clinical setting.
Included in series
Handbook of Immunopharmacology
Audience:
Research level pharmacologists, immunologists, and cell biologists; as a reference text in this area for those involved in degree-level teaching. Pharmaceutical companies.
